Customer Center

SSamyang Group News

Samyang Group News
Samyang Biopharmaceuticals Corp. Signs Technology Transfer Agreement with KIST for Anticancer Immunotherapy Drug Print
Affiliates Samyang Biopharm Writer administrator Hits 4615 Date 2018.01.16


Samyang Biopharmaceuticals Corp. is accelerating the development of new biological anticancer drugs through open innovation.


Samyang Biopharmaceuticals Corp. revealed that they held a signing ceremony with the Korea Institute of Science and Technology (KIST) for the technology transfer of the new Nanocage on the 16th at the main branch of KIST in Seoul. The new technology introduced by Samyang Biopharmaceuticals Corp. is an anticancer immunotherapy drug delivery system that binds immune checkpoint inhibitors to the surface of a Nanocage containing an anticancer drug.


The immune checkpoint inhibitors bound to the surface of the Nanocage strengthens the body’s immune system and activates the attack of immunocytes on cancer cells. The anticancer drug embedded in the interior of the Nanocage directly attacks and kills cancer cells. Samyang Biopharmaceuticals Corp. plans to develop a new anticancer immunotherapy drug utilizing this technology.


Anticancer immunotherapy drugs are classified as 3rd generation anticancer drugs. They are drugs that treat cancer by causing immunocytes within the body to attack cancer cells. Anticancer immunotherapy drugs block the channel by which cancer cells attack immunocytes(immune checkpoint inhibitors), or strengthen the immunocytes to help them attack the cancer cells.


The global anticancer immunotherapy drug market is expected to increase by about 20 times from $1.4 billion in 2014 to $27.6 billion in 2020.


In the future, Samyang Biopharmaceuticals Corp. plans to develop a new anticancer immunotherapy drug by conducting clinical tests in which Samyang Biopharmaceuticals Corp.’s anticancer drug is embedded on the Nanocage before being administered or clinical tests for the Nanocage alone, after conducting a proof of concept with KIST.


Representative EOM Tae-Ung of Samyang Biopharmaceuticals Corp. explained said, “Samyang Biopharmaceuticals Corp. is pursuing open innovation through active cooperation with other institutes. With the introduction of KIST’s new Nanocage technology, Samyang Biopharmaceuticals Corp. will accelerate the development of new biopharmaceuticals.” Samyang Biopharmaceuticals Corp. is a specialized affiliate of Samyang Group’s biopharmaceutical business, with about 200 head office and research staff currently working at Samyang Discovery Center in Pangyo.


Samyang Biopharmaceuticals Corp. has secured growth momentum by trailblazing the global market with its distinctive technology in the medicine and medical device (MD) field, and is focusing its research and development in three key areas: ▲improved drug products using drug delivery systems (DDS) ▲new biopharmaceuticals to lead the future anticancer treatment and ▲medical devices (MD) using cutting-edge biodegradable materials.


이전 다음글 제목을 나타낸 표
Prev Samyang Corporation concludes Technology Transfer Agreement of Oxime Photoinitiator with the Korea Research Institute of Chemical Technology 2018.01.23
Next Samyang Biopharmaceuticals Corp. Wins ‘Palseron Inj.’ Patent Suit 2018.01.03